Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 8, 2010

Forest Laboratories Pays TransTech Pharma $50M Up Front in Diabetes Deal

  • Forest Laboratories is paying TransTech Pharma $50 million in a collaboration related to the former’s glucose-lowering agents for the treatment of diabetes. TransTech Pharma could earn a total of $1.105 billion in up-front and milestone fees.

    The license agreement covers the development and commercialization of these small molecule compounds, which are functionally liver-selective glucokinase activators (GKAs). The licensed candidates include lead compound, TTP399, which has completed Phase I studies and other molecules in Phase I and preclinical stages.

    Forest will also pay royalties on worldwide product sales and will be responsible for development and commercialization costs. TransTech Pharma retains rights to the Middle East and North Africa, while Forest receives exclusive rights to the rest of the worldwide market.

    TransTech Pharma’s compounds are covered by composition of matter patents and applications, which currently, in the case of the lead compound TTP399, extend to 2025. The firm has identified a series of liver selective GKA compounds and has advanced three compounds to Phase I trials, including TTP399. The company believes that by activating glucokinase selectively in the liver but not in the pancreas, it may increase glucose utilization and lower blood glucose levels without inducing excessive insulin secretion thus reducing the risk of hypoglycemia.

Readers' Comments

Posted 06/09/2010 by Evelyn Guzman

Forest Laboratories Pays TransTech Pharma $50M Up Front in Diabetes Deal
Wow, imagine paying $50 million for the treatment of diabetes.  And do you know what it is for?  For the blood sugar lowering agents that Trans Tech Pharma is working on, that's what.  Forest Laboratories must have some kind of inside information to fork out that much money.  I can only hope Trans Tech Pharma succeeds not for the sake of Forest Laboratories so they can recoup their substantial investment but for the sake of all the diabetics whose life will become more manageable.   
Evelyn Guzman
http://www.free-symptoms-of-diabetes-alert.com  (If you want to visit, just click but if it doesn’t work, copy and paste it onto your browser.)

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »